Lexaria Bioscience Corp. LEXX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-63.83
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $705,923 | -$11.9M | $703,203 | -$10.5M | $2.6M |
| 2024 | $464,278 | -$5.8M | $459,456 | -$5.0M | $7.7M |
| 2023 | $226,208 | -$6.7M | $194,708 | -$5.9M | $2.7M |
| 2022 | $255,397 | -$7.3M | $183,556 | -$4.9M | $7.6M |
| 2021 | $722,738 | -$4.0M | $547,392 | — | $13.1M |
| 2020 | $314,793 | -$4.1M | $215,415 | -$2.6M | $2.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| BUNKA CHRISTOPHER | director | 2026-03-17 | Gift | 100,000 | — |
| BUNKA CHRISTOPHER | director | 2025-07-30 | Buy | 11,900 | $0.91 |
| DOCHERTY JOHN MARTIN | President & CSO | 2025-07-29 | Buy | 5,376 | $0.93 |
| Carle Vanessa | Secretary | 2025-07-29 | Buy | 750 | $0.91 |
| CHRISTOPHER RICHARD | Chief Executive Officer | 2025-07-29 | Buy | 15,000 | $0.91 |
| McKechnie William Edward | director | 2025-07-29 | Buy | 5,000 | $0.91 |
| BUNKA CHRISTOPHER | director | 2025-07-29 | Buy | 15,600 | $0.92 |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -63.83 (distress)
- Working capital / assets 0.473
- Retained earnings / assets -15.2
- EBIT / assets -2.846
- Equity / liabilities 1.655
Source: SEC EDGAR filings · CIK 0001348362 · as of 2025-08-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.